The Dow Jones Industrial Average index is up more than 50 points since opening today, but the Nasdaq...
The Dow Jones Industrial Average index is up more than 50 points since opening today, but the Nasdaq Composite is down 7 points, mixed signals that cannot but have influenced thinking in London before the LSE closed today.
The optimists are still, however, in charge, and the FTSE 100 index has ended the day up 88.60 points at 4,279.20, nearly 300 points off the 5-year low reached on Monday.
Schroders has closed the day as the best performer, as its shares gained 35.5p to 525.5p.
Talk of an advertising rebound has seen BSkyB shares jump 39p to 607p.
Northern Rock, which unveiled positive results today, is up 40.5p at 670.5p.
Granada has followed BSkyB, putting on 5.25p to 104.25p.
Shell and Unilever have been caught in events out of their control as the closing auction on their shares has been delayed due to the S&P index rebalancing that is seeing a raft of top European firms kicked out in favour of good 'ol US champs.
The rebalancing has been severely criticised by many fund managers as a part-protectionist move to give US equities a boost in times of weak equities prices at the expense of European firms whose shares are traded in New York.
Shell is unchanged at present, but Unilever has shed 3p to 545.5p.
Centrica leads the losing group, down 4p to 168.75p as the market continues to calculate the cost to the gas futures market of the closure of the main pipeline between the UK and Europe for maintenance.
The big mid-cap winner is engineer Amey, which today announced it would spend less money bidding for contracts - shares rocketed more than 25% or 23.5p to 117p.
Software provider Misys saw its shares end up 39p at 220p after it said it would sell shares in its troubled financial adviser business.
Surprisingly on the day that mobile phone company MmO2 announced good new subscriber figures, Carphone Warehouse shares lost 8.75p to 74.5p.
Irish drugs company Galen lost another 15p to 340p after Goldman Sachs downgraded its recommendation on Novartis, Europe's third biggest pharmaceutical company.
Partner Insight: Continuing the Architas education series for clients.
What made financial headlines over the weekend?
290,000 already affected
Putting the tech into protection
Square Mile’s series of informal interviews